Advanced Rectal Cancer Clinical Trial
Official title:
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Although neoadjuvant chemoradiotherapy has significantly reduced the risk of local recurrence in locally advanced rectal cancer, systemic failure remains a predominant issue probably due to the insufficient control of systemic micro-metastasis in the neoadjuvant treatment. Induction chemotherapy is one of the most studied strategies. However, the efficacy of induction chemotherapy prior to neoadjuvant chemotherapy remains controversial. In our previous study, induction chemotherapy, gap chemotherapy combined with neoadjuvant chemoradiotherapy can improve response rate of rectal cancer patients, but the results have not been confirmed in clinical trial. Whether this new kind of treatment can optimize neoadjuvant therapy for locally advanced rectal cancer or not is still a big problem in clinical practice. This study will focus on how to optimize neoadjuvant chemotherapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03156036 -
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC
|
Phase 2 | |
| Active, not recruiting |
NCT03781323 -
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05228431 -
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05359393 -
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
|
Phase 2 | |
| Not yet recruiting |
NCT05359406 -
A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis
|
Phase 2 | |
| Suspended |
NCT01872104 -
Safety and Efficiency of Photodynamic Therapy for Rectal Cancer
|
Phase 2/Phase 3 |